The case for & against
Bull & Bear analysis
Delcath Systems (NASDAQ: DCTH) is a biotechnology company that specializes in developing innovative therapies for treating cancers that primarily affect the liver, notably metastatic uveal melanoma. The company's flagship product, Hepsado, utilizes a unique hepatic delivery system for localized drug administration, which enhances treatment efficacy while minimizing systemic exposure. Positioned at the forefront of a niche oncology market, Delcath aims to expand its therapy's accessibility through active treatment center initiatives and strategic partnerships with leading cancer institutions.
Bull says
- ↑Q1 2026 revenue $25M (+26% YoY), driven by Hepsado sales of $23.3M
- ↑Gross margin at 85% underscores high treatment profitability
- ↑$89.3M cash on hand, no debt provides operational runway
- ↑Aiming for 37 active treatment centers by end-2026 to boost volumes
- ↑Expected Chopin trial data publication could accelerate physician adoption
- ↑Strong Buy consensus with $21 median target implies ~70% upside
Bear says
- ↓Q1 2026 net loss of $1.1M highlights ongoing profitability shortfall
- ↓Negative profitability and weak earnings revisions cast doubt on returns
- ↓Pace of center activations slowed; target revised due to execution challenges
- ↓Seasonal summer patient volume dips risk undermining revenue forecasts
- ↓High leverage and liquidity risk may constrain financial flexibility
- ↓Weak future earnings revisions suggest potential value trap
Investment themes with DCTH
Clinical instruments and devices powering patient care
Stocks with highest short interest
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Total revenue in the first quarter of 2026 was $25 million compared with $19.8 million in the first quarter of 2025. This included $23.3 million of his auto kit revenue and $1.7 million of chemo stat revenue.
- We ended the quarter with $89.3 million in cash investments and no debt.
- We also purchased approximately 300,000 common shares for about $3 million in the first quarter under the company's approved $25 million share buyback program.
Bear points
- Research and development expenses in the first quarter was $9.8 million compared to $5 million in the prior quarter, driven primarily by continued investment in our clinical organization in the ongoing phase two trial.
- Selling general and administrative expense in the first quarter was $13.1 million compared to $11.3 million in the prior year quarter. This reflects our investment into the continued commercial expansion and increased marketing activities.
- Net loss for the first quarter was $1.1 million compared to net income of $1.1 million in the prior year first quarter.